Targeting the target: a step forward for the treatment of non-small-cell lung cancer

Comment

. 2010 Feb;11(2):104-5.

doi: 10.1016/S1470-2045(09)70390-0.

Comment

Jean Yves Douillard. Lancet Oncol. 2010 Feb.

. 2010 Feb;11(2):104-5.

doi: 10.1016/S1470-2045(09)70390-0.

No abstract available

Comment on

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.

Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA. Carbone DP, et al. J Thorac Oncol. 2012 Nov;7(11):1653-60. doi: 10.1097/JTO.0b013e31826c1155. J Thorac Oncol. 2012. PMID: 23059783 Free PMC article. Clinical Trial.
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Wu X, et al. Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013. Onco Targets Ther. 2013. PMID: 24204163 Free PMC article.